ロード中...
In MDS, is higher risk higher reward?
Patients with higher-risk myelodysplastic syndrome (HR-MDS) are defined by the original or revised International Prognostic Scoring System and specific genetic features. Treatment of HR-MDS is challenging. Allogeneic hematopoietic stem cell transplantation, the only curative approach, is feasible in...
保存先:
| 出版年: | Hematology Am Soc Hematol Educ Program |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913486/ https://ncbi.nlm.nih.gov/pubmed/31808894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000042 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|